↓ Skip to main content

Safety evaluation of intravenous immunoglobulin in pediatric patients: a retrospective, 1-year observational study

Overview of attention for article published in Therapeutic Advances in Drug Safety, October 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#35 of 302)
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news
2 news outlets
twitter
2 X users

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safety evaluation of intravenous immunoglobulin in pediatric patients: a retrospective, 1-year observational study
Published in
Therapeutic Advances in Drug Safety, October 2019
DOI 10.1177/2042098619876736
Pubmed ID
Authors

Reem Elajez, Asmaa Ezzeldin, Hossamaldein Gaber

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Lecturer 3 20%
Librarian 2 13%
Researcher 2 13%
Student > Doctoral Student 2 13%
Other 1 7%
Other 3 20%
Unknown 2 13%
Readers by discipline Count As %
Medicine and Dentistry 7 47%
Pharmacology, Toxicology and Pharmaceutical Science 3 20%
Agricultural and Biological Sciences 1 7%
Linguistics 1 7%
Social Sciences 1 7%
Other 1 7%
Unknown 1 7%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 November 2019.
All research outputs
#1,828,538
of 23,166,665 outputs
Outputs from Therapeutic Advances in Drug Safety
#35
of 302 outputs
Outputs of similar age
#41,146
of 350,302 outputs
Outputs of similar age from Therapeutic Advances in Drug Safety
#2
of 13 outputs
Altmetric has tracked 23,166,665 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 302 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.1. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,302 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.